Literature DB >> 4366246

Hydroxyproline in the early diagnosis of bone metastases in prostatic cancer.

M J Kontturi, E A Sotaniemi, T K Larmi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4366246     DOI: 10.3109/00365597409132111

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


× No keyword cloud information.
  5 in total

1.  Study of hydroxyproline excretion in patients with prostatic cancer.

Authors:  I Romics; I Budavári; L Kisbenedek; F Balogh
Journal:  Int Urol Nephrol       Date:  1981       Impact factor: 2.370

2.  Urinary hydroxyproline levels in patients with prostatic carcinoma.

Authors:  D Erol; N Adalar; S Güvençli; F Simşek
Journal:  Int Urol Nephrol       Date:  1983       Impact factor: 2.370

3.  Free serum hydroxyproline and total urinary hydroxyproline for the detection of skeletal metastasis.

Authors:  A B Gasser; D Depierre; B Mermillod; B Courvoisier
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

4.  Total urinary and free serum hydroxyproline in metastatic bone disease.

Authors:  A B Gasser; D Depierre; B Courvoisier
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640

5.  Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis.

Authors:  M Sano; K Kushida; M Takahashi; T Ohishi; K Kawana; M Okada; T Inoue
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.